SPRINGWORKS THERAPEUTICS, INC. (SWTX) News
Filter SWTX News Items
SWTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SWTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SWTX News From Around the Web
Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.
SpringWorks Therapeutics price target lowered to $78 from $80 at GuggenheimGuggenheim analyst Michael Schmidt lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $78 from $80 and keeps a Buy rating on the shares. The firm has “modestly adjusted” its Ogsiveo estimates, reflecting lower assumptions for ovarian granulosa cell tumor contribution and a more gradual sales ramp in 2025 in the EU, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stock |
SpringWorks Therapeutics Stock Gets A RS Rating LiftSpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating |
High Growth Tech Stocks to Watch in January 2025The United States market has experienced a flat performance over the past week, but it is up 24% over the past year with earnings anticipated to grow by 15% annually in the coming years. In such an environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looking for companies with strong innovation and potential to sustain robust revenue expansion. |
SpringWorks Therapeutics price target lowered to $55 from $58 at BofABofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $55 from $58 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of invest |
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSTAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at http |
High Growth Tech Stocks to Watch in December 2024The United States market has experienced a flat performance over the last week but has seen an impressive 32% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In this environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong potential for innovation and scalability, aligning well with these optimistic growth expectations. |
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceSTAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media sect |
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter ReportShareholders of SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) will be pleased this week, given that the stock price is... |
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...SpringWorks Therapeutics Inc (SWTX) reports a 23% revenue increase and anticipates FDA approval for a new treatment, despite short-term challenges. |
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare ConferenceSTAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section o |